<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3841">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397692</url>
  </required_header>
  <id_info>
    <org_study_id>BAI_COV19_01_US</org_study_id>
    <nct_id>NCT04397692</nct_id>
  </id_info>
  <brief_title>Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)</brief_title>
  <official_title>Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beyond Air Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beyond Air Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open label, randomized, study is to obtain information on the safety and&#xD;
      efficacy of 80 ppm Nitric Oxide given in addition to the standard of care of patients with&#xD;
      COVID-19 caused by SARS-CoV-2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nitric Oxide (NO) is a small endogenously produced molecule recognized to play a critical&#xD;
      role in the function of several body systems including the vasodilatation of smooth muscle,&#xD;
      neurotransmission, regulation of wound healing and inhibition of pathogens. In-vitro studies&#xD;
      have shown that NO inhibits the replication cycle of the severe acute respiratory syndrome&#xD;
      coronavirus (SARS CoV) in vitro. The suggested mechanisms of actions of NO on SARS are an&#xD;
      effect on the fusion between the S protein and its cognate receptor, ACE2, and reduction in&#xD;
      viral RNA production in the early steps of viral replication. The primary aim of this&#xD;
      feasibility study is to investigate the safety of intermittent NO, delivered via inhalation,&#xD;
      in hospitalized patients with COVID-19. The primary endpoint in the study will be time to&#xD;
      deterioration of respiratory symptoms determined by escalation to either non-invasive&#xD;
      ventilation (NIV), high-flow nasal cannula (HFNC), or intubation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to deterioration</measure>
    <time_frame>14 Days</time_frame>
    <description>Time to deterioration measured by need for NIV, HFNC or intubation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to NIV</measure>
    <time_frame>14 Days</time_frame>
    <description>Time to non-invasive ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to HFNC</measure>
    <time_frame>14 Days</time_frame>
    <description>Time to high flow nasal cannula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to intubation</measure>
    <time_frame>14 days</time_frame>
    <description>Time to intubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to patient having stable oxygen saturation (SpO2) of greater than or equal to 93%</measure>
    <time_frame>14 days</time_frame>
    <description>Time to patient having stable oxygen saturation (SpO2) of greater than or equal to 93%</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Need for supplemental oxygen</measure>
    <time_frame>14 days</time_frame>
    <description>Need for supplemental oxygen</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in viral load</measure>
    <time_frame>30 days</time_frame>
    <description>Change in viral load</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of the Hospital Length of Stay (LOS)</measure>
    <time_frame>14 days</time_frame>
    <description>Duration of the Hospital Length of Stay (LOS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality rate at Day 30</measure>
    <time_frame>30 days</time_frame>
    <description>Mortality rate at Day 30</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Corona Virus Infection</condition>
  <condition>COVID-19</condition>
  <condition>SARS-CoV 2</condition>
  <condition>Nitric Oxide</condition>
  <condition>Respiratory Disease</condition>
  <condition>Pneumonia, Viral</condition>
  <condition>Inhaled Nitric Oxide</condition>
  <arm_group>
    <arm_group_label>Inhaled NO delivered using LungFit™ in addition to SST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 80 ppm iNO for 40 min 4 times a day using LungFit™ device in addition to the standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control - Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nitric Oxide delivered via LungFit™ system</intervention_name>
    <description>Patients will receive inhalations of 80 ppm for 40 min 4 times a day</description>
    <arm_group_label>Inhaled NO delivered using LungFit™ in addition to SST</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Enrollment within 24 hours of hospital admission of patients diagnosed with COVID-19&#xD;
&#xD;
          -  Patients with oxygen saturation less than 93 % on room air&#xD;
&#xD;
          -  Shortness of breath, with symptom onset within the previous 8 days.&#xD;
&#xD;
          -  Female subjects of childbearing potential should take adequate measures to avoid&#xD;
             pregnancy&#xD;
&#xD;
          -  Signed informed consent by the subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are treated with or require high flow nasal cannula, CPAP, intubation,&#xD;
             mechanical ventilation, or tracheostomy&#xD;
&#xD;
          -  Diagnosis of acute respiratory distress syndrome&#xD;
&#xD;
          -  Subjects diagnosed with immunodeficiency, with history of congestive or unstable heart&#xD;
             disease, left ventricular dysfunction or myocardial damage, severe pulmonary&#xD;
             hypertension and/or unstable hypertension&#xD;
&#xD;
          -  Patients receiving drugs that have contraindications with NO.&#xD;
&#xD;
          -  Breastfeeding or pregnancy as evidenced by a positive pregnancy test.&#xD;
&#xD;
          -  Patients with active pulmonary malignancy or lung transplant&#xD;
&#xD;
          -  Patients with a history of frequent epistaxis or significant hemoptysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashik Tal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Beyond Air</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vladislava Zamfirova</last_name>
    <phone>+1-410-236-4368</phone>
    <email>vzamfirova@beyondair.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enoch Bortey</last_name>
    <email>ebortey@beyondair.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baptist Health Center for Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priyantha Wijewardane, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Inhaled Nitric Oxide</keyword>
  <keyword>iNO</keyword>
  <keyword>SARS-coronavirus</keyword>
  <keyword>Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

